Lantern Pharma Inc LTRN

NAS: LTRN | ISIN: US51654W1018   14/11/2024
3,490 USD (-1,13%)
(-1,13%)   14/11/2024

3 mei 2023 · Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial · Persbericht

12 mei 2022 · Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month · Persbericht

3 mei 2022 · Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights · Persbericht

26 april 2022 · Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors · Persbericht

22 april 2022 · Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET · Persbericht

22 maart 2022 · Lantern Pharma Announces Extension of Existing Share Repurchase Program · Persbericht

14 maart 2022 · Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting · Persbericht

10 maart 2022 · Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights · Persbericht

3 maart 2022 · Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 · Persbericht

15 februari 2022 · Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio · Persbericht

24 januari 2022 · Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System · Persbericht

18 januari 2022 · Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors · Persbericht

12 januari 2022 · Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284 · Persbericht

4 januari 2022 · Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference · Persbericht

14 december 2021 · Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting · Persbericht

22 november 2021 · Lantern Pharma Announces Share Repurchase Program · Persbericht

12 november 2021 · Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day · Persbericht

11 november 2021 · Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting · Persbericht

9 november 2021 · Lantern Pharma to Participate in Two Upcoming Investor Conferences · Persbericht

4 november 2021 · Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting · Persbericht

Mijn selecties